Ilkin Muradov

Dr. Ilkin Muradov


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
IMIlkin Muradov
Ilkin Muradov
SŞSerdar Şahin
Serdar Şahin
SUSerhat Uysal
Serhat Uysal
CScem sulu
cem sulu
PGPelinsu Gunebakan
Pelinsu Gunebakan
PKPınar Kadıoğlu
Pınar Kadıoğlu

10 July 2026 in Endocrine
Verified
Journal Article
Closed access
PDF file
IMIlkin Muradov
Ilkin Muradov
SUSerhat Uysal
Serhat Uysal
BKbanu betül kocaman
banu betül kocaman
LSLala Soltanova
Lala Soltanova
OKOgulcan Karali
Ogulcan Karali
EDEmre Durcan
Emre Durcan

26 December 2025 in Pituitary
Verified
Journal Article
Closed access
PDF file
BKbanu betül kocaman
banu betül kocaman
YCYusuf Cicek
Yusuf Cicek
SŞSerdar Şahin
Serdar Şahin
ADAhmet Burhan Dogan
Ahmet Burhan Dogan
SUSerhat Uysal
Serhat Uysal
PKPınar Kadıoğlu
Pınar Kadıoğlu

8 March 2026 in Clinical Endocrinology
Verified
Journal Article
Closed access
IMIlkin Muradov
Ilkin Muradov
SŞSerdar Şahin
Serdar Şahin
SASumeyye Akpinar
Sumeyye Akpinar
ATAli Tunc
Ali Tunc
BKbanu betül kocaman
banu betül kocaman
PKPınar Kadıoğlu
Pınar Kadıoğlu

8 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
LSLala Soltanova
Lala Soltanova
CİCeren İşeri
Ceren İşeri
SŞSerdar Şahin
Serdar Şahin
MKMihriban Kara
Mihriban Kara
SGSuzan Aydin Guclu
Suzan Aydin Guclu
PKPınar Kadıoğlu
Pınar Kadıoğlu
Purpose: The aims of this study were to evaluate the feasibility of time-restricted eating (TRE) in patients with Cushing’s disease (CD) and assess its effects on body weight and metabolic parameters. Methods: Twelve CD patients in remission with obesity were enrolled in a TRE program restricting food intake to 10:00–18:00. Anthropometric data, glycemic and lipid profiles, and circadian cortisol secretion were assessed at baseline and post-intervention. Serum cortisol levels were measured at multiple time points to evaluate diurnal patterns. Results: Nine patients completed the study. Over the 12-week period, participants showed a significant reduction in body weight, with median values decreasing from 93.8 kg [83.1–106.5] to 82.6 kg [76.9–100.3] (p = 0.011). Body mass index (BMI) also declined from 37.6 kg/m2 [34.2–39.7] to 34.4 kg/m2 [32.6–38.3] (p = 0.012). No statistically significant changes were observed in fasting glucose, HbA1c, or lipid parameters. Notably, 24 h urinary free cortisol levels significantly decreased (p = 0.01), and serum cortisol showed a downward trend at all measured time points, with the most pronounced reductions during mid-day and evening hours. No clinical or biochemical evidence of CD relapse was observed during the 12-month follow-up. Conclusions: Time-restricted eating is a feasible and well-tolerated dietary approach for patients with CD in remission, promoting weight loss and modest improvements in metabolic markers and cortisol rhythmicity.

2 April 2026 in Endocrine
Verified
Journal Article
Open access
PDF file
LSLala Soltanova
Lala Soltanova
AAAhmet Bera Aygun
Ahmet Bera Aygun
BKbanu betül kocaman
banu betül kocaman
IMIlkin Muradov
Ilkin Muradov
STSabriye Sibel Taze
Sabriye Sibel Taze
EDEmre Durcan
Emre Durcan
Background: We aim to investigate the potential link between the physical changes associated with acromegaly and the development of alexithymia, as well as its related psychopathological outcomes and impact on quality of life. Methods: The study included 137 patient with acromegaly and 125 control group patients. Body Image Scale (BIS), Toronto Alexithymia Score-20 (TAS-20), Hospital Anxiety and Depression inventory (HAD), Short Form-36 (SF-36) and Acromegaly Quality of Life Scale (AcroQol) were used to the patients. Results: In the acromegaly group, TAS-20 total scores, as well as the Difficulty Identifying Feelings (DIF) and Difficulty Describing Feelings (DDF) subscale scores, were higher compared to the control group (51 vs. 44, p < 0.01; 16 vs. 12, p < 0.01; and 12 vs. 11, p < 0.01, respectively). In contrast, no notable difference was observed in the Externally Oriented Thinking (EOT) scores between the groups. The prevalence of alexithymia was markedly higher in individuals with acromegaly (16.7%) than in the control group (3.2%, p < 0.001). A positive correlation was found between alexithymia and both depression and anxiety scores ( r = 0.469, p < 0.001; r = 0.377, p < 0.01, respectively). In contrast, alexithymia was negatively correlated with SF-36, AcroQoL and BIS ( r = − 0.426, p < 0.01; r = − 0.465, p < 0.01; r = − 0.364, p < 0.01, respectively). Patients with acromegaly reported poorer body image and a higher rate of impaired body perception compared to control group (43.7% vs. 19.2%, p < 0.01). Conclusion: The present study demonstrates that alexithymia is more prevalent in patients with acromegaly compared to controls and often persists even after remission.